ObservInsulin vs Oral Anti-diabetic Drugs in Diabetic Patients Undergoing PCI
Data Collection
Collected at a single point in time - Cross-sectionalDiabetes Mellitus+2
+ Endocrine System Diseases
+ Metabolic Diseases
Other
Utilizing specific methods not covered by standard models in order to address unique research questions.Summary
Study start date: May 20, 2025
Actual date on which the first participant was enrolled.This study focuses on understanding how different treatments for diabetes, specifically insulin versus oral anti-diabetic drugs (OADs), affect heart health after a heart attack in people with diabetes. Diabetes increases the risk of heart problems, and when someone with diabetes has a heart attack, they often need a procedure called percutaneous coronary intervention (PCI) to open blocked heart arteries. However, diabetic patients typically experience more complications during and after this procedure compared to non-diabetic individuals. This research is important because finding the best diabetes treatment to use during PCI could improve recovery and reduce heart-related complications for these patients. In this observational study, participants with diabetes who undergo PCI after a heart attack are divided into two groups based on their diabetes treatment: those receiving insulin and those taking oral anti-diabetic drugs. The study observes and compares the short-term heart health outcomes of both groups, specifically looking for major adverse cardiovascular events. This includes any serious issues like heart attacks, strokes, or other significant heart complications that occur shortly after the procedure. By comparing these outcomes, researchers hope to determine which treatment might lead to better heart health in diabetic patients after PCI.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.210 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Patients with DM (type 2) undergoing primary PCI for STEMI.1- Treated with either insulin or OADs prior to admission.2- 3- Age ≥18 year Exclusion Criteria: * Type 1 DM.1- Patients on both insulin and OADs.2- 3-Prior coronary artery bypass graft (CABG) surgery. 4-Severe renal impairment (eGFR \<30 mL/min/1.73m²). 5-Hemodynamically unstable patients 6-moderate to severe VHD 7-Patients who were shifted from OADs to insulin during Follow-up
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location